EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy

Iryna Halabitska, Iryna Kamyshna, Pavlo Petakh, Inna Krynytska, Denis Putilin, Oleksandr Kamyshnyi

Acta Diabetologica · 2026

DOI: 10.1007/s00592-026-02647-y ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Diabetologica, 2026. Verfasst von Iryna Halabitska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Ternopil, 46001, Ukraine. Hauptthemen laut MEDLINE: Metformin, Metabolic Syndrome, Obesity, Hypoglycemic Agents. Die Arbeit nennt 118 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obesity includes a wide range of metabolic conditions. Some patients remain metabolically healthy despite excess body weight (MHO phenotype), while others develop metabolic syndrome and metabolic dysfunction–associated fatty liver disease (MAFLD). These differences may determine the risk of diabetes and cardiovascular disease. The present study compared clinical and biochemical characteristics between people with MHO and those with MetS combined with MAFLD, and evaluated the effects of six months of metformin therapy in the latter group. METHODS: A total of 78 adults with obesity (BMI ≥ 30 kg/m2) were examined. Participants were classified as MHO (n = 26) or as having metabolic syndrome with MAFLD (n = 52). Anthropometric data, glucose and lipid metabolism indicators, liver enzymes, and non-invasive measures of hepatic steatosis and fibrosis (CAP, FIB-4, HSI) were recorded. Patients with MetS + MAFLD were randomized to lifestyle modification (Mediterranean diet and moderate exercise) or the same program plus metformin (500 mg twice daily) for six months. RESULTS: After six months, patients in the metformin group showed significant improvements in fasting glucose (− 0.9 ± 0.4 mmol/L, p < 0.001), HbA1c (− 0.5 ± 0.2%, p < 0.001), and HOMA-IR (p < 0.001), accompanied by modest weight reduction (− 1.6 ± 0.8 kg, p = 0.02). ALT and AST decreased (p = 0.001 and p = 0.003, respectively), and CAP values fell by 9% (p = 0.004). Fibrosis indices FIB-4 and HSI both improved (p < 0.001). Triglycerides (p = 0.01) and blood pressure (p < 0.05) decreased, while HDL-cholesterol increased (p = 0.02). CONCLUSIONS: People with MHO showed preserved metabolic function and no signs of fatty liver despite similar BMI. In patients with metabolic syndrome and MAFLD, metformin treatment for six months led to meaningful improvement in glucose control, liver function, and lipid profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminMetabolic SyndromeObesityHypoglycemic AgentsHumansFemaleMiddle AgedMaleAdultBlood GlucoseFatty Liver

Stichwörter der Autor:innen

Insulin resistanceMetabolic associated fatty liver diseaseMetabolic syndromeMetforminObesity

Substanzen

MetforminHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Department of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Ternopil, 46001, Ukraine.
  • Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, 46001, Ukraine.
  • Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine. pavlo.petakh@uzhnu.edu.ua.
  • Department of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil National Medical University, Ternopil, 46001, Ukraine.
  • Department of Otorhinolaryngology, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, 69035, Ukraine.
  • Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, 46001, Ukraine. kamyshnyi_om@tdmu.edu.ua.

Zitieren

APA

Halabitska, I., Kamyshna, I., Petakh, P., Krynytska, I., Putilin, D., & Kamyshnyi, O. (2026). Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy. Acta Diabetologica. https://doi.org/10.1007/s00592-026-02647-y

Vancouver

Halabitska I, Kamyshna I, Petakh P, Krynytska I, Putilin D, Kamyshnyi O. Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy. Acta Diabetologica. 2026. doi:10.1007/s00592-026-02647-y

BibTeX
@article{Halabitska2026,
  author = {Halabitska, Iryna and Kamyshna, Iryna and Petakh, Pavlo and Krynytska, Inna and Putilin, Denis and Kamyshnyi, Oleksandr},
  title = {Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy},
  journal = {Acta Diabetologica},
  year = {2026},
  doi = {10.1007/s00592-026-02647-y}
}
Kostenlos starten →